Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management

Recruiting now · Not applicable

Conditions studied: Venous Thromboembolic Event

In brief

This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients

Key facts

Study ID

NCT07464808

Run by

Ain Shams University

People needed

25

Starts

2025-11-28

Expected to finish

2027-11-30

Last updated by the study team

2026-03-11

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥21 years) admitted to the burn unit with thermal burns ≥20% TBSA and < 60%.
• Admission to BICU within 48 hours of burn injury.
• Indication for VTE prophylaxis (e.g., immobilized, surgical intervention).
• Ability to provide informed consent

You may not qualify if…

• Pre-existing coagulopathy or anticoagulant therapy prior to injury.
• Patients with severe comorbidities (e.g., end-stage renal failure, advanced malignancy, hepatic disease).
• Need for therapeutic anticoagulant therapy.
• patients with extremes of weight, (45kg >=weight >= 150kg).

Where it is running

• Ain Shams University — Cairo, Abbassia, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.